Mechanism of action, potency and efficacy: considerations for cell therapies by Carl G. Simon, Erich H. Bozenhardt, Christina M. Celluzzi, David Dobnik, Melanie L. Grant, Uma Lakshmipathy, Thiana Nebel, Linda Peltier, Anthony Ratcliffe, James L. Sherley, Glyn N. Stacey, Rouzbeh R. Taghizadeh, Eddie H. P. Tan, Sandrine Vessillier

Subjects: Get full text

Randomized controlled trial data for successful new drug application for rare diseases in the United States by Yosuke Kubota, Mamoru Narukawa

Subjects: Get full text

Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review by Jingqiu Li, Xiaoding Zhou, Lei Wu, Jiabao Ma, Yan Tan, Songke Wu, Jie Zhu, Qifeng Wang, Qiuling Shi

Subjects: “…Early efficacy endpoint…”
Get full text

Advantages of Lissamine Green Vital Staining as an Endpoint in Dry Eye Clinical Trials by Rodriguez JD, Kerti S, Hamm A, Ousler GW, Bensinger E, Burnham S, Abelson MB

Subjects: Get full text